In Phase C, participants will obtain ABBV-744 and oral navitoclax. In Segment D, individuals will obtain ABBV-744 and ruxolitinib. Participants will receive treatment right until sickness progression or the contributors are unable to tolerate the study drugs. Celastrol was recognized as being a Myb inhibitor that suppressed C/EBPβ exercise and https://abbv-744andotherbrd4inhib13579.slypage.com/32574811/abbv-744-clinical-trial-phase-2-data-things-to-know-before-you-buy